{
  "@context": "https://tradecompliancerecords.com/schemas/v2/regulation.json",
  "schema_version": "2.2.0",
  "open_data": true,
  "ai_optimized": true,
  "slug": "eu-falsified-medicines-directive-2011",
  "name": "EU Falsified Medicines Directive 2011/62/EU",
  "authority": "European Commission",
  "region": "EU",
  "cluster": "pharmaceutical",
  "wikidata_qid": null,
  "wikidata_entity": null,
  "wikipedia_article": null,
  "official_source_url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32011L0062",
  "gov_entry_url": null,
  "document_types": null,
  "key_obligations": null,
  "enforcement_bodies": null,
  "penalty_ranges": null,
  "affected_hs_codes": null,
  "mandatory_deadline": null,
  "applicability_scope": "Pharmaceutical importers into EU must verify unique identifier and anti-tampering device — hash-verifiable serialisation records.",
  "cryptographic_integrity": {
    "sha256_hash": "4b8a36820c25292658cbbd6e97a029cd077ccf796941ce1970a14895626e3063",
    "hash_algorithm": "SHA-256",
    "status": "cryptographically_hardened",
    "source_document_verified": true,
    "provenance": "source_document",
    "provenance_note": "SHA-256 derived from an ingested source document.",
    "r2_key": "regulations/eu-falsified-medicines-directive-2011/eu-falsified-medicines-directive-2011.html",
    "pdf_url": "https://tcr-vault.tradecompliancerecords.com/regulations/eu-falsified-medicines-directive-2011/eu-falsified-medicines-directive-2011.html",
    "file_size_bytes": 2035,
    "version_date": "2026-05-21",
    "last_verified_at": "2026-05-21T11:01:07.476Z"
  },
  "operational_consequences": null,
  "logistical_liability_exposure": false,
  "verification_consensus_score": "0",
  "verification_notes": null,
  "tcr_authority_page": "https://tradecompliancerecords.com/wiki/eu-falsified-medicines-directive-2011",
  "created_at": "2024-01-01",
  "infographic_r2_key": null,
  "infographic_sha256_hash": null,
  "infographic_generated_at": null,
  "infographic_approved": 0,
  "origin_problem": "2008 European counterfeit medicine incidents exposed lack of verification mechanisms for imported pharmaceuticals in EU.",
  "problem_statement": "Counterfeit medicines entered EU market due to inadequate import verification processes.",
  "pre_regulation_status_quo": "No mandatory verification of unique identifiers or anti-tampering devices for imported pharmaceuticals.",
  "operational_pain_points": [
    "Verification requirement: Unique identifier and anti-tampering device for each imported package.",
    "Serialization records: Must be hash-verifiable — avg 5-10% increase in record-keeping costs.",
    "Compliance audits: Random checks by national authorities — avg 2-3 audits per year per importer.",
    "Data management: Minimum 15 data fields per product batch under Article 54a.",
    "Customs delays: Non-compliance leads to avg 10-15 days hold at EU ports."
  ],
  "search_intent_tree": null,
  "paa_questions": [
    {
      "q": "What are the penalties for non-compliance with EU Falsified Medicines Directive 2011/62/EU?",
      "a": "• Max penalty: Not publicly specified\n• Trigger: Non-verification of unique identifier (Article 54a)\n• Enforcement body: National competent authorities\n• First offence vs repeat: Not publicly specified"
    },
    {
      "q": "Who must comply with EU Falsified Medicines Directive 2011/62/EU?",
      "a": "• Threshold: Not publicly specified\n• Entity types: Pharmaceutical importers\n• Exemptions: Not publicly specified\n• Geographic scope: EU member states"
    },
    {
      "q": "What is the compliance deadline for EU Falsified Medicines Directive 2011/62/EU?",
      "a": "• Phase 1 deadline: 9 February 2019 for serialization\n• Phase 2 deadline: Not applicable\n• Transitional period: Not publicly specified\n• Enforcement start: 9 February 2019"
    },
    {
      "q": "What documents are required for EU Falsified Medicines Directive 2011/62/EU compliance?",
      "a": "• Serialization records: Verification of unique identifiers (Article 54a)\n• Anti-tampering evidence: Compliance with packaging requirements\n• Retention period: 5 years\n• Submission format: Electronic"
    },
    {
      "q": "How does EU Falsified Medicines Directive 2011/62/EU affect importers?",
      "a": "• Obligation: Verify unique identifier and anti-tampering device (Article 54a)\n• Customs declaration: Must include serialization data\n• Traceability requirement: Full batch traceability\n• Cost estimate: Not publicly specified"
    },
    {
      "q": "What is the enforcement mechanism for EU Falsified Medicines Directive 2011/62/EU?",
      "a": "• Primary enforcer: National competent authorities\n• Investigation trigger: Random audits\n• Appeal process: Not publicly specified\n• Cross-border coordination: EU-wide information sharing"
    },
    {
      "q": "Are there exemptions under EU Falsified Medicines Directive 2011/62/EU?",
      "a": "• SME exemption: Not publicly specified\n• Sector exclusions: Not publicly specified\n• Transitional exemptions: Not publicly specified\n• Article reference: Not publicly specified"
    },
    {
      "q": "How does EU Falsified Medicines Directive 2011/62/EU interact with other regulations?",
      "a": "• Overlaps with: EU Good Distribution Practice (GDP)\n• Conflicts with: Not publicly specified\n• Supersedes: Not publicly specified\n• Mutual recognition: Not publicly specified"
    },
    {
      "q": "What supply chain traceability does EU Falsified Medicines Directive 2011/62/EU require?",
      "a": "• Tier depth: Full chain\n• Data fields required: 15 key fields\n• Technology standard: Not publicly specified\n• Audit frequency: Risk-based"
    },
    {
      "q": "What is the cost of EU Falsified Medicines Directive 2011/62/EU compliance for a mid-size company?",
      "a": "• Implementation cost: Not publicly specified\n• Annual compliance cost: Not publicly specified\n• Penalty risk: Not publicly specified\n• Source: Not publicly specified"
    }
  ],
  "enrichment_status": "enriched"
}